Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
City of Hope Medical Center
Mayo Clinic
University of Nebraska
Mayo Clinic
M.D. Anderson Cancer Center
Acerta Pharma BV
H. Lee Moffitt Cancer Center and Research Institute
Thomas Jefferson University
Case Comprehensive Cancer Center
Thomas Jefferson University
Thomas Jefferson University
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
University of Colorado, Denver
Stanford University
Barbara Ann Karmanos Cancer Institute
Masonic Cancer Center, University of Minnesota
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
Columbia University
Fred Hutchinson Cancer Center
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Thomas Jefferson University
Thomas Jefferson University
JaxBio Ltd
Cedars-Sinai Medical Center
Ohio State University Comprehensive Cancer Center
Cedars-Sinai Medical Center
Advice Pharma Group srl
Mundipharma Research Limited
Roswell Park Cancer Institute
A.O. Ospedale Papa Giovanni XXIII
OHSU Knight Cancer Institute
Memorial Sloan Kettering Cancer Center
Beth Israel Deaconess Medical Center
Washington University School of Medicine
University of Nebraska
University of Nebraska
University of Birmingham
Fred Hutchinson Cancer Center